Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Spinal Diseases: HELP
Articles by Cláudia C. Vaz
Based on 2 articles published since 2008
||||

Between 2008 and 2019, Cláudia Vaz wrote the following 2 articles about Spinal Diseases.
 
+ Citations + Abstracts
1 Guideline Portuguese recommendations for the use of biological therapies in patients with axial spondyloarthritis - 2016 update. 2017

Machado, Pedro / Cerqueira, Marcos / Ávila-Ribeiro, Pedro / Aguiar, Renata / Bernardo, Alexandra / Sepriano, Alexandre / Águeda, Ana / Cordeiro, Ana / Raposo, Ana / Rodrigues, Ana M / Barcelos, Anabela / Malcata, Armando / Lopes, Carina / Vaz, Cláudia C / Nour, Dolores / Godinho, Fátima / Alvarenga, Fernando / Pimentel-Santos, Fernando / Canhão, Helena / Santos, Helena / Cunha, Inês / Neves, Joana Sousa / Fonseca, João Eurico / Gomes, João Lagoas / Tavares-Costa, José / Costa, Lúcia / Cunha-Miranda, Luís / Maurício, Luís / Cruz, Margarida / Afonso, Maria Carmo / Santos, Maria José / Bernardes, Miguel / Valente, Paula / Figueira, Ricardo / Pimenta, Sofia / Ramiro, Sofia / Pedrosa, Teresa / Costa, Tiago Afonso / Vieira-Sousa, Elsa. ·University College London, London, UK. · Rheumatology Department, Unidade Local de Saúde do Alto Minho, Hospital Conde de Bertiandos, Ponte de Lima, Portugal. · Rheumatology and Metabolic Bone Diseases Department, Centro Hospitalar Lisboa Norte, Hospital de Santa Maria, Lisboa, Portugal. · Rheumatology Department, Centro Hospitalar do Baixo Vouga, Hospital de Aveiro, Aveiro, Portugal. · Rheumatology Department, Centro Hospitalar de S. João, Porto, Portugal. · NOVA Medical School, Universidade Nova de Lisboa, Lisboa, Portugal. · Rheumatology Department, Hospital Garcia de Orta, Almada, Portugal. · Rheumatology Department, Centro Hospitalar de Trás-os-Montes e Alto Douro, Vila Real, Portugal. · CEDOC, EpiDoC Unit, NOVA Medical School and National School of Public Health, Universidade Nova de Lisboa, Lisboa, Portugal. · Rheumatology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal. · CEDOC, EpiDoC Unit, NOVA Medical School and National School of Public Health, Universidade Nova de Lisboa; Rheumatology Department, Centro Hospitalar Lisboa Ocidental, Hospital de Egas Moniz, Lisboa, Portugal. · Rheumatology Department, Unidade Local de Saúde da Guarda, Guarda, Portugal. · Clínica Intregare Terapêutica - Fortaleza: Clínica da Família, Fortaleza, Brasil. · Consultório Privado de Reumatologia, Portugal. · Instituto Português de Reumatologia, Lisboa, Portugal. · Rheumatology and Metabolic Bone Diseases Department, Centro Hospitalar Lisboa Norte, Hospital de Santa Maria; Rheumatology Research Unit, Instituto de Medicina Molecular, Faculty of Medicine, University of Lisbon, Lisbon Academic Medical Centre, Lisbon, P. · Rheumatology Department, Centro Hospitalar Lisboa Ocidental, Hospital de Egas Moniz, Lisboa, Portugal. · Centro Hospitalar de Entre o Douro e Vouga, Hospital de São Sebastião, Santa Maria da Feira, Portugal. · Centro Hospitalar do Funchal, Funchal, Madeira, Portugal. · NOVA Medical School, Universidade Nova de Lisboa; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands. ·Acta Reumatol Port · Pubmed #28894079.

ABSTRACT: OBJECTIVE: To update the recommendations for the treatment of axial spondyloarthritis (axSpA) with biological therapies, endorsed by the Portuguese Society of Rheumatology. METHODS: These treatment recommendations were formulated by Portuguese rheumatologists based on literature evidence and consensus opinion. At a national meeting, the 7 recommendations included in this document were discussed and updated. A draft of the full text of the recommendations was then circulated and suggestions were incorporated. A final version was again circulated before publication and the level of agreement among Portuguese Rheumatologists was anonymously assessed using an online survey. RESULTS: A consensus was achieved regarding the initiation, assessment of response and switching of biological therapies in patients with axSpA. In total, seven recommendations were produced. The first recommendation is a general statement indicating that biological therapy is not a first-line drug treatment option and should only be used after conventional treatment has failed. The second recommendation is also a general statement about the broad concept of axSpA adopted by these recommendations that includes both non-radiographic and radiographic axSpA. Recommendations 3 to 7 deal with the definition of active disease (including the recommended threshold of 2.1 for the Ankylosing Spondylitis Disease Activity Score [ASDAS] or the threshold of 4 [0-10 scale] for the Bath Ankylosing Spondylitis Disease Activity Index [BASDAI]), conventional treatment failure (nonsteroidal anti-inflammatory drugs being the first-line drug treatment), assessment of response to treatment (based on an ASDAS improvement  of at least 1.1 units or a BASDAI improvement of at least 2 units [0-10 scale] or at least 50%), and strategy in the presence of an inadequate response (where switching is recommended) or in the presence of long-term remission (where a process of biological therapy optimization can be considered, either a gradual increase in the interval between doses or a decrease of each dose of the biological therapy). CONCLUSION: These recommendations may be used for guidance in deciding which patients with axSpA should be treated with biological therapies. They cover a rapidly evolving area of therapeutic intervention. As more evidence becomes available and more biological therapies are licensed, these recommendations will have to be updated.

2 Guideline 2011 Portuguese recommendations for the use of biological therapies in patients with psoriatic arthritis. 2012

Machado, Pedro / Bogas, Mónica / Ribeiro, Ana / Costa, José / Neto, Adriano / Sepriano, Alexandre / Raposo, Ana / Cravo, Ana Rita / Vilar, António / Furtado, Carolina / Ambrósio, Catarina / Miguel, Cláudia / Vaz, Cláudia / Catita, Cristina / Nour, Dolores / Araújo, Domingos / Vieira-Sousa, Elsa / Teixeira, Filipa / Brandão, Filipe / Canhão, Helena / Cordeiro, Inês / Gonçalves, Inês / Ferreira, Joana / Fonseca, João Eurico / da Silva, José Alberto Pereira / Romeu, José / Ferreira, Júlia / Costa, Lúcia / Maurício, Luís / Cunha-Miranda, Luís / Parente, Manuela / Coutinho, Margarida / Cruz, Margarida / Oliveira, Margarida / Salvador, Maria João / Santos, Maria José / Pinto, Patrícia / Valente, Paula / Abreu, Pedro / Roque, Raquel / Ramiro, Sofia / Capela, Susana / Las, Vera / Barcelos, Anabela / Anonymous1620731. ·Serviço de Reumatologia, Hospitais da Universidade de Coimbra, Praceta Prof. Mota Pinto, 3000-075 Coimbra, Portugal. pedrommcmachado@gmail.com ·Acta Reumatol Port · Pubmed #22781512.

ABSTRACT: OBJECTIVE: To develop recommendations for the treatment of psoriatic arthritis (PsA) with biological therapies, endorsed by the Portuguese Society of Rheumatology. METHODS: These treatment recommendations were formulated by Portuguese rheumatologists based on literature evidence and consensus opinion. A draft of the recommendations was first circulated to all Portuguese rheumatologists and their suggestions were incorporated in the draft. At a national meeting the recommendations were discussed and all attending rheumatologists voted on the level of agreement for each recommendation. A second draft was again circulated before publication. RESULTS: A consensus was achieved regarding the initiation, assessment of response and switching biological therapies in patients with PsA. Specific recommendations were developed for several disease domains: peripheral arthritis, axial disease, enthesitis and dactylitis. CONCLUSION: These recommendations may be used for guidance in deciding which patients with PsA should be treated with biological therapies. They cover a rapidly evolving area of therapeutic intervention. As more evidence becomes available and more biological therapies are licensed, these recommendations will have to be updated.